Galectin Therapeutics Inc. (GALT)

[biotech2010]

You keep making these accusations that I have 'gone off the rails' regarding my perspective regarding GALT and the management team. I have refrained from making any personal remarks about you and your alleged expertise but that is over, as is my interaction with you.

As for the Alpha 2 Macroglobulin results and market not being of interest to GALT or Traber, then WHY DID IT OCCUPY THREE FULL SLIDES IN THEIR REPORT OF THE PHASE 1 TRIAL? http://files.shareholder.com/downloads/AMDA-235HJQ/0x0x793096/b9052389-3853-46eb-9e07-f6e293878b23/AASLDPresentation110914.pdf

Other than safety, this marker is the ONLY clinical result that would give anyone a reason to believe that GR-MD-02 has a reasonable chance of succeeding and that chance seems to diminish on a monthly basis as their cash starts to run out with no action from the company to lower operating costs. To claim that providing any input about the use of this market going forward is just plain idiotic.

I am finished discussing this with you at any level other than you have your opinion, I have mine and they are as different as different can be. I believe that when you are a senior executive you have a FIDUCIARY RESPONSIBILITY to maximize shareholder value, not your own bank account, something Traber and his team have no problem doing through pay increases, retention bonuses, and whatever else they can pull out of the company.